We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microneedle Patch Detects Skin Cancer Early

By LabMedica International staff writers
Posted on 31 May 2024
Print article
Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet)
Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet)

Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes. Despite its advancements, there has been a lack of progress specifically in the area of cancer, and more notably in skin cancer detection. Researchers have now introduced a novel technique for identifying malignant melanoma, which is the most serious type of skin cancer and also the fastest growing.

A groundbreaking study conducted by researchers at Karolinska Institutet (Stockholm, Sweden) led to the development of a new type of patch equipped with microneedles designed to detect the biomarker tyrosinase directly within the skin. Tyrosinase is an enzyme that serves as a crucial biomarker for malignant melanoma. By assessing the enzyme directly in the skin, this approach allows for the rapid detection of changes indicative of the disease. The feasibility of this transdermal microneedle sensor for directly quantifying tyrosinase has been demonstrated in an ex vivo skin model.

In their research, scientists employed human tissue samples from healthy individuals. They applied tyrosinase to these samples to simulate the presence of skin cancer. Their findings suggest that this new patch could serve as an effective alternative to traditional diagnostic techniques, facilitating earlier detection and treatment of malignant melanoma. The researchers are optimistic that their invention will reduce the need for invasive procedures and enhance the quality of life for patients. This innovation marks a significant step forward in improving skin health monitoring and could potentially be adapted to detect other biomarkers simply by altering its design.

“Our method is less invasive and has the potential to provide faster and more reliable results compared to traditional biopsies,” said Onur Parlak, Associate Professor at Karolinska Institutet. “Our goal is to continue developing and improving this technique to offer more accurate and painless diagnostics.” 

Related Links:
Karolinska Institutet

New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
New
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Zonulin ELISA
IDK Zonulin (Serum) ELISA
New
Enterovirus Infection Test
Virotech Enterovirus IgM ELISA Kit

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.